XELOX in colorectal cancer: a convenient option for the future?. (February 2011)

• Record Type: Journal Article
• Authors: Lindsay, Colin R; Cassidy, Jim
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 5:Number 1(2011)
• Page Start: 9
• Page End: 19
• Publication Date: 2011-02
• Subjects: cancer -- capecitabine -- colorectal -- oxaliplatin -- XELOX; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1586/egh.10.90
• Languages: English
• ISSNs: 1747-4124

Abstract

XELOX is a 3-weekly chemotherapy combination of oral capecitabine and intravenous oxaliplatin. The central hypothesis that led to its development was that it would provide a convenient and cost-effective alternative to intravenous fluorouracil-based chemotherapy doublets, without compromising on anti-tumor efficacy. Recently its role in colorectal cancer has become more established in both the metastatic and adjuvant setting. Ongoing investigation of XELOX continues in a number of directions: its combination with novel biological agents, its efficacy and safety in the elderly, and the development of biomarkers that can predict its anti-tumor effect. This article provides a comprehensive and up-to-date synopsis of all pertinent clinical studies detailing this regimen and its promise for the future.